Covance 💯 Top

It is an Angiotensin II Receptor Blocker (ARB) that relaxes blood vessels to lower pressure and ease heart strain.

Covance was acquired by Labcorp in 2015 and officially rebranded as Labcorp Drug Development in 2021. In 2023, the clinical development portion was spun off as an independent company named Fortrea . Key Services: COVANCE

Reduces the risk of in patients with an enlarged heart. Protects kidney function in patients with Type 2 diabetes. It is an Angiotensin II Receptor Blocker (ARB)